Company ProfilePremium

Immuron Limited

Company Profile Analysis

Ticker: IMC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Immuron Limited - Company showcase

Year Founded & Workforce

1994

7 Employees

Immuron Limited logo

Immuron Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Immuron Limited Overview

Immuron is an Australian commercial- and clinical-stage biopharmaceutical micro-cap built on a proprietary platform of orally delivered polyclonal antibodies harvested from the colostrum of dairy cows immunised against specific gut pathogens. Its economic engine today is Travelan®, an over-the-counter tablet for reducing the risk of travellers' diarrhoea, sold as a listed medicine in Australian pharmacy, a natural health product in Canada and a dietary supplement in the United States; Travelan generated essentially all of FY2026 revenue of A$7.71 million. Gross margins are attractive (64.5% in FY2026) but the business remains loss-making after sales, marketing and corporate costs. Behind the consumer franchise sit two FDA-IND-stage prescription assets — IMM-124E (travellers' diarrhoea) and IMM-529 (Clostridioides difficile infection) — which, following a February 2026 "Strategic Reset", management now intends to out-license rather than fund through Phase 3. The investment case is therefore a hybrid of a small, growing consumer-health brand and binary partnering optionality on the pipeline.


Company's own description (FY2026 Form 20-F, paraphrased)

In its FY2026 annual report on Form 20-F, Immuron describes itself as a commercial and clinical-stage biopharmaceutical company whose proprietary technology platform develops and commercialises a novel class of specifically targeted polyclonal antibodies aimed at significant unmet medical needs. It currently markets Travelan® and ProIBS® in Australia (both listed on the Australian Register of Therapeutic Goods — Travelan AUST L 106709; ProIBS AUST L 482225), Travelan in Canada as a licensed natural health product (NPN 80046016), and Travelan in the U.S. as a dietary supplement for digestive tract protection. Protectyn® (AUST L 231001), previously sold online and through practitioner clinics as an immune/digestive supplement, was cancelled and removed from the ARTG in June 2026. The company emphasises that its antibodies act within the gastrointestinal tract and do not enter the bloodstream, which it believes supports safety and tolerability.

The 20-F's liquidity section describes a "two-pronged" value-creation approach: in the short to medium term, sell and license the Travelan OTC product; beyond that, research and clinically develop products principally for travellers' diarrhoea and C. difficile infection.

Platform technology

Pregnant dairy cows are immunised with vaccines containing antigens of human enteric pathogens. The resulting hyper-immune bovine colostrum (HBC) is rich in pathogen-specific IgG. According to the company, bovine IgG survives gastric acid and resists proteolysis, remaining active in the human GI tract where it binds bacteria, blocks colonisation and neutralises toxins. IMM-124E (the active in Travelan) is generated from cows vaccinated with outer antigens of 13 human-derived enterotoxigenic E. coli (ETEC) strains; the colostrum contains antibodies against ETEC LPS, CFA-I and flagellin. IMM-529 targets three C. difficile virulence components — Toxin B, spores and surface-layer proteins of vegetative cells — and was developed with Dr Dena Lyras' group at Monash University.

Business model and revenue model

Revenue model elementFY2026 contributionComment
Product sales (OTC consumer health)100% of revenue from contracts with customers (A$7.71m)Travelan 98.6%, ProIBS 1.1%, Protectyn 0.3%
Licensing / royalties0%Management intends to out-license IMM-124E and IMM-529; no deal signed as of October 2026
Contract research / manufacturing servicesFirst revenue received May 2026 under the DoD/HJF Campylobacter–Shigella program (amount not separately disclosed); HJF R&D grant A$339,819 booked as other income20-F risk factors reference "our ability to successfully expand our contract manufacturing services"
Subscriptions / services——
Non-operating supportAustralian R&D Tax Incentive (A$782,313 audited, FY2026) and R&D grants (HJF A$339,819) recorded in other incomeMaterial relative to revenue; proposed May 2026 reforms may end eligibility (Section 18)

Value-chain position

Immuron is an asset-light brand owner and IP holder. It does not own farms or factories. Hyper-immune colostrum for IMM-124E is produced by Bovogen Biologicals (Australia); finished Travelan product is made by contract manufacturers including Mayne Pharma International; IMM-529 GMP process development is with Syntro Health (FY2026 20-F risk factors). Immuron controls vaccine/antigen know-how, regulatory dossiers, brand, marketing and distribution relationships. Downstream, it sells through pharmacy wholesalers and retailers in Australia (notably Chemist Warehouse/Sigma), Amazon and online channels in the U.S., and pharmacy chains in Canada (including Jean Coutu in Québec from Q3 FY2026).

Customer types and end-markets

Customer typeEnd-marketProducts
Pharmacy wholesalers and retail chains (Australia)Consumer travel health; digestive health/IBSTravelan, ProIBS
E-commerce (Amazon U.S.) and U.S. retailConsumer dietary supplements / travel healthTravelan
Canadian pharmacy chains (>1,000 doors listed in FY2025; Jean Coutu, Québec, FY2026)Natural health products / travel healthTravelan
U.S. Department of Defense research bodies (NMRC, WRAIR via Henry M. Jackson Foundation)Military force-health protection R&DBespoke HBC products for pre-clinical evaluation
Future pharma licensees (sought)Prescription anti-infectives (TD prophylaxis; CDI)IMM-124E, IMM-529

Independent characterisation

Immuron is best understood as a sub-scale consumer-health brand company carrying a legacy biotech cost structure and listing burden (dual ASX/Nasdaq). Travelan has demonstrably scaled post-COVID — revenue rose roughly tenfold from FY2022 to FY2026 — but growth decelerated sharply to 5.9% in FY2026 as the post-pandemic travel rebound normalised and Canada's pipeline-fill comparison unwound. The prescription pipeline has been de-risked regulatorily (two INDs) but not clinically for the commercial dosing regimen in a field setting: the December 2025 military field study missed its primary endpoint, albeit with a third-party product dosed off-label. The February 2026 pivot to partnering is an explicit admission that the balance sheet cannot fund Phase 3. Value therefore depends on (a) whether Travelan can sustain double-digit growth and reach EBITDA (ex-R&D) breakeven, and (b) whether IMM-529 in particular can attract a licensee on terms that matter relative to a ~US$14 million market capitalisation.

Strategy

Stated strategy themes

"Make Travelan the must-have travel essential": for consumers and retailers (FY2025 sales release, July 2025).

Strategic Reset (25 February 2026): pursue partnerships to fund progress of IMM-124E and IMM-529 rather than self-fund late-stage trials; focus internal capital on the consumer franchise. Management positioned Immuron as no longer a "concept" company, citing consistent revenue growth as a competitive moat.

EBITDA (ex-R&D) breakeven: as the near-term financial objective (AGM, 11 November 2025).

FY2027 plan (28 August 2026): invest to grow North America while maintaining Australian momentum, with quarterly milestones: Q1 continued Travelan growth; Q2 portfolio expansion; Q3 IMM-529 partnering progress; Q4 geographic expansion, improved profitability and reduced cash burn.

Initiatives in the last 24 months

InitiativeDateDescriptionStatus
ProIBS in-licensing and launchAgreement 2025; launch 24 Oct 2025Exclusive ANZ distribution of Calmino's AVH200-based IBS product; first portfolio extension beyond hyper-immune productsLaunched; A$85k FY2026 revenue
Canadian channel expansionFY2025–FY2026Pipeline fill into >1,000 stores; Jean Coutu (Québec) listing; in-store education and promotionsQ4 FY2026 sales up several-fold YoY
U.S. digital marketingFY2025–FY2026Amazon optimisation, targeted messaging, social-media influencer campaignsU.S. +13% in USD FY2026
Australian brand refreshQ4 FY2026New Travelan packaging and creativeLaunched
IMM-529 INDSubmitted Oct 2025; approved Nov 2025Phase 2 enabling (first-episode and recurrent CDI)Phase 2 contingent on partner
Partnering programFeb 2026 onwardOut-license IMM-124E and IMM-529; Pullan Consulting engaged for IMM-529 (6 Jul 2026)Ongoing; no deal announced
DoD Campylobacter/Shigella programDec 2025Produce two HBC products for pre-clinical evaluation under HJF collaborative agreementFirst revenue May 2026
AFRIMS testingDec 2025Test Travelan against EAEC/EPEC to inform a broader military-relevant formulationDiscussions advanced
Cost programFY2026R&D cut 46%; G&A cut 4%Net loss improved A$1.4–1.5m
Capital managementJul–Dec 2025; Jun 2026ATM raises (~A$7.1m gross); unmarketable parcel buy-backCompleted
ESG / sustainability commitments—None disclosed—

Medium-term targets / guidance

Management guided (February 2026) that 2H FY2026 and FY2026 net sales and net profit would exceed the prior comparative periods; both were achieved. No quantitative FY2027 revenue or profit guidance has been published; the FY2027 framework is qualitative.

Products & Services

Hyper-immune Products (commercial)

Travelan® (IMM-124E, caplets)

  • Description: purified tablet of hyper-immune bovine colostrum antibodies against 13 ETEC strains plus other colostrum factors; taken with/before meals to bind diarrhoea-causing bacteria and prevent colonisation.

  • Regulatory status/claims: Australia — ARTG listed medicine AUST L 106709, indicated to reduce risk of travellers' diarrhoea and minor GI disorders, and antimicrobial; Canada — natural health product NPN 80046016 to reduce risk of TD; U.S. — dietary supplement for digestive tract protection.

  • Dosing: one to two caplets before each meal (three times daily), per the 10 December 2025 release.

  • Target customer: leisure and business travellers to high-risk (lower/middle-income) destinations; secondarily military/deployed personnel.

  • Channels: Australian pharmacy (Chemist Warehouse/Sigma and other banners), Amazon U.S., Canadian pharmacy (>1,000 doors; Jean Coutu from Q3 FY2026).

  • Launch: available in Australia since the Anadis era (Canada distribution from 2005); U.S. and Canada launches under Anastasiou-era board (2013–2024). New packaging and creative launched in Q4 FY2026 (StockWireX summary of 16 July 2026 release).

  • Pricing: not publicly disclosed in sources reviewed.

  • FY2026 revenue: A$7.607m (Australia 5.673, U.S. 1.768, Canada 0.166).

ProIBS® (in-licensed)

  • Description: CE/TGA-listed medical product containing AVH200®, derived from Aloe barbadensis Mill., which forms a hydrogel film supporting the intestinal mucosal barrier; for relief of symptoms of medically diagnosed IBS (abdominal pain, bloating, diarrhoea and/or constipation). Developer: Calmino group AB (Sweden). Calmino's usability study of 1,003 users reported 94% found it helpful (company-cited, not peer-reviewed).

  • Regulatory: ARTG AUST L 482225.

  • Rights: exclusive distribution for Australia and New Zealand.

  • Launch: officially launched in Australia 24 October 2025.

  • Target customer: adults with IBS (company cites healthdirect estimate that ~3 in 10 people are affected).

  • FY2026 revenue: A$0.085m (first partial year).

Protectyn® (discontinued)

  • Description: hyper-immune colostrum immune supplement marketed to support healthy digestive function and liver.

  • Status: cancelled and removed from ARTG June 2026.

  • Revenue: FY2023 A$0.060m; FY2024 A$0.043m; FY2025 A$0.049m; FY2026 A$0.022m.

Research and Development (clinical and pre-clinical)

AssetIndicationMechanismStage (Oct 2026)Key dataCommercial estimateStrategy
IMM-124E (Rx Travelan)Prevention of travellers' diarrhoea (ETEC)Anti-ETEC polyclonal IgG (LPS, CFA-I, flagellin)FDA IND approved Dec 2022; eligible for End-of-Phase 2 (EOP2) meetingOtto et al. 2011 CHIM: 90.5% protection (n=30, 400mg TID); 58–83% (n=60); 2024 Phase 2 CHIM: 36.4% protective efficacy once-daily 1200mg (attack rate 37%); USU P2TD field study missed primary endpoint (third-party 600mg sachet BID)Lumanity peak U.S. sales US$102mPartner (Strategic Reset Feb 2026); propose TID caplet regimen at EOP2
IMM-529C. difficile infection — treatment and prevention of recurrence, adjunct to antibioticsThree-target HBC: Toxin B, spores, surface-layer proteinsFDA IND 32095 approved Nov 2025; Phase 2-readyPre-clinical: 80% prevention of primary disease (P=0.0052); 67% protection vs recurrence (P<0.01); 78.6% treatment of primary disease (P<0.0001) (Hutton et al., Sci Rep 2017)Lumanity peak U.S. sales US$400mPartner; Pullan Consulting engaged 6 Jul 2026
DoD Campylobacter / Shigella HBC productsMilitary-relevant enteric infectionsTwo HBC products from NMRC/WRAIR-developed vaccinesPre-clinical; first revenue May 2026——Funded by DoD sub-award via Henry M. Jackson Foundation
CampETEC (NMRC)Campylobacter + ETECHBC manufactured by Immuron from NMRC vaccinePhase 2 CHIM completed 2024Interim 10.4% protective efficacy (n=27)—Collaboration; no further development disclosed
Travelan vs EAEC/EPEC (AFRIMS testing)Broader E. coli coverageTesting existing productDiscussions advanced (Dec 2025)——Could add a vaccine to IMM-124E manufacturing
IMM-986Not specified in sources—Pre-clinical (Yahoo Finance profile)——Status not disclosed

Financial Narrative

All figures A$ millions unless stated; fiscal years ended 30 June. Sources: FY2023 Appendix 4E (FY2022 comparatives), FY2024 Appendix 4E (FY2023 comparatives), FY2026 Appendix 4E (FY2025 audited comparatives), FY2026 Form 20-F (FY2026 audited net loss).

Income statement

FY2026 net loss per preliminary 4E: A$3.839m; per audited 20-F: A$3.680m.

Margins and growth

Revenue CAGR FY2022–FY2026 (4 years): 78.2%. Revenue CAGR FY2023–FY2026 (3 years): 62.3%. Both are flattered by the COVID-depressed FY2022 base; the FY2026 growth rate of 5.9% is the more relevant run-rate indicator.

Commentary — P&L. The five-year arc has three phases. FY2022–FY2023 was recovery from near-zero travel: revenue of A$0.77m in FY2022 more than doubled in FY2023 as borders reopened. FY2024–FY2025 was the inflection: revenue rose 171.7% and then 48.6% on Australian pharmacy expansion (FY2024 Australian Travelan sales of A$3.7m vs A$1.1m in FY2023), U.S. Amazon traction and the Canadian pipeline fill. FY2026 was normalisation: growth slowed to 5.9% as Canada lapped its pipeline fill (-56%) and Chemist Warehouse/Sigma reduced Travelan inventories under a supply-chain efficiency program, a one-off headwind the company says it absorbed while still growing Australia 10%.

Gross margin has drifted down ~8 points from FY2023's 72.5% to 64.5%. Plausible drivers (not quantified by the company) include channel mix toward large pharmacy groups, promotional pricing in Canada, inventory provisioning effects (FY2023 benefited from a A$0.43m inventory-provision release), and the strong Australian dollar compressing U.S.-dollar sales translated to A$ (U.S. sales +13% in USD but +7% in AUD in FY2026).

The improvement in the bottom line in FY2026 is driven overwhelmingly by R&D, which fell A$1.66m (-46%) as the company stopped self-funding clinical work after the USU study read out and the Strategic Reset took effect. Selling and marketing was held flat at ~A$3.47m and G&A fell 4%. Critically, the business is still not profitable before R&D: FY2026 gross profit of A$4.98m did not cover S&M plus G&A of A$7.78m, a A$2.80m gap that was partially bridged by A$1.0–1.2m of R&D tax incentive and grant income. Management's stated target is "EBITDA (ex-R&D) breakeven" (AGM 11 November 2025; defined as EBITDA adding back R&D, less R&D tax incentive and grants).

Balance sheet

Notes: FY2023–FY2024 "lease liabilities" are the "other current/non-current liabilities" lines, which analyst judgement treats as lease liabilities. Goodwill/intangibles are taken as nil because NTA calculations exclude only right-of-use assets. FY2026 balance sheet is 4E basis; the audited 20-F implies a higher R&D tax receivable (A$782,313 vs A$623,613) and therefore slightly higher assets and equity. FY2025 NTA as restated in FY2026 4E (3.45c) vs 3.39c originally reported.

Commentary — balance sheet. Immuron is debt-free and has never relied on borrowings. Equity has been eroded from A$23.2m (FY2022) to A$8.1m (FY2025) by cumulative losses before the FY2026 ATM raises rebuilt it to A$11.0m. The liquidity low point was 30 June 2025, when cash plus term deposits stood at A$5.87m against an annual operating outflow of A$6.1m — this explains the aggressive ATM usage in July–December 2025. The share count rose 38% in FY2026 (233.96m to 322.85m), the single largest dilution event in the company's recent history. Inventory of A$2.27m equals roughly 300 days of FY2026 COGS, which is high and warrants monitoring for obsolescence given colostrum shelf-life.

Cash flow

Commentary — cash flow. Operating burn roughly halved in FY2026 to A$3.26m as R&D was cut and DoD grant funding (MTEC in FY2023–FY2024, HJF in FY2026) offset some program costs. Note the FY2023–FY2024 burn was cushioned by A$3.1m and A$1.9m of MTEC grant receipts that have now ended. FY2026 FCF of -A$3.26m against A$9.0m of cash implies roughly 2.5–3 years of runway at the FY2026 rate, consistent with the Emerging Growth Research note (March 2026) that capital provides runway "into 2027" at then-expected spend; however, management has flagged FY2027 investment in North American growth, which could lift burn before the targeted Q4 FY2027 reduction. The FY2026 buy-back (A$0.12m) was an unmarketable-parcel clean-up, not a capital-return program.

Ratios

Net debt/EBITDA and interest coverage are not meaningful (net cash; negative EBIT; no interest-bearing debt). ROIC is not meaningful given negative NOPAT and an invested-capital base dominated by cash. A full cash-conversion cycle is not computed because trade payables include operating-expense creditors and cannot be isolated against COGS. FY2026 ROE/ROA use audited net loss and 4E balance sheet.

Ratio commentary. Return metrics are deeply negative but improving; asset turnover has risen from 0.26x to 0.67x as revenue scaled against a shrinking asset base. Inventory days have improved from >500 to ~270 but remain elevated for a consumer product, reflecting long colostrum production lead-times and batch economics.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / activities

Hyper-immune Products

Commercial OTC portfolio and related inventory, marketing, distribution

Travelan (AU, US, CA), ProIBS (AU; in-licensed, not hyper-immune technology but reported within this revenue line), Protectyn (discontinued June 2026)

Research and Development

Clinical and pre-clinical programs; government/DoD-funded research

IMM-124E (TD Rx), IMM-529 (CDI), DoD Campylobacter/Shigella HBC program, platform research

Revenue by Segment

SegmentFY2024FY2025FY2026

Hyper-immune Products revenue (AUD Mn)

4.9037.2877.714

Research and Development external revenue (AUD Mn)

000

Total revenue from contracts with customers (AUD Mn)

4.9037.2877.714

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

Segment metricFY2024FY2025FY2026

Hyper-immune Products revenue YoY growth (%)

171.748.65.9

Hyper-immune Products share of total revenue (%)

100100100

Hyper-immune Products gross margin (%)

68.165.464.5

Hyper-immune Products segment profit (AUD Mn)

—1.35—

R&D segment expense (AUD Mn, consolidated R&D line)

5.3753.5971.933

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

0.7651.8054.9037.2877.714

Revenue YoY growth (%)

—135.8171.748.65.9

Cost of goods sold (AUD Mn)

—0.4961.5662.5222.739

Gross profit (AUD Mn)

—1.3093.3374.7654.975

Other income incl. R&D tax incentive and grants (AUD Mn, 4E basis)

—2.5913.4081.4121.011

General and administrative expenses (AUD Mn)

—4.2214.5564.4844.306

Research and development expenses (AUD Mn)

—2.5925.3753.5971.933

Selling and marketing expenses (AUD Mn)

—0.9272.0303.4523.472

Operating loss (AUD Mn, 4E basis)

-2.870-3.569-5.801-5.345-4.009

EBITDA (AUD Mn, operating loss plus disclosed depreciation)

—-3.520-5.755——

Share of loss/impairment of associate Ateria (AUD Mn)

0-0.324-1.45600

Pre-tax loss (AUD Mn, 4E basis)

-2.854-3.787-6.937-5.216-3.839

Income tax (AUD Mn)

00000

Net loss (AUD Mn, audited where available)

-2.854-3.787-6.937-5.216-3.680

Basic and diluted EPS (A cents, 4E basis)

-1.25-1.66-3.04-2.26-1.29

Dividends per share (A cents)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

—72.568.165.464.5

Operating margin (%, 4E basis)

-375.0-197.8-118.3-73.3-52.0

EBITDA margin (%)

—-195.0-117.4——

Net margin (%, audited where available)

-373.0-209.8-141.5-71.6-47.7

R&D as % of revenue (%)

—143.6109.649.425.1

Selling and marketing as % of revenue (%)

—51.441.447.445.0

G&A as % of revenue (%)

—233.992.961.555.8

Balance Sheet and Share Count (millions)

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (AUD Mn)

—21.98815.55010.13012.993

Cash and cash equivalents (AUD Mn)

22.11017.16011.6572.8319.018

Term deposits classified as other current assets (AUD Mn)

—003.0360

Cash plus term deposits (AUD Mn)

22.11017.16011.6575.8679.018

Borrowings short-term (AUD Mn)

—0000

Borrowings long-term (AUD Mn)

—0000

Lease liabilities total (AUD Mn)

—0.1890.1730.1170.190

Net debt incl. leases, negative = net cash (AUD Mn)

—-16.971-11.484-5.750-8.828

Total equity (AUD Mn)

23.17719.61712.7098.06911.006

Goodwill and intangibles (AUD Mn)

—0000

Inventories current plus non-current (AUD Mn)

—2.0602.2541.7732.274

Trade and other receivables (AUD Mn)

0.6630.4171.3881.9261.250

Total current assets (AUD Mn)

—20.40914.72610.01512.800

Total current liabilities (AUD Mn)

—2.2192.6991.9661.786

Working capital (AUD Mn)

—18.19012.0278.04911.015

Accumulated losses (AUD Mn)

68.42572.05578.96882.44385.129

Ordinary shares outstanding (millions)

227.798227.798227.998233.959322.848

Net tangible assets per share (A cents)

—8.535.513.453.35

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Receipts from customers (AUD Mn)

—1.9134.7347.5938.480

R&D tax incentive refund received (AUD Mn)

—0.2520.3950.7681.111

Grants received (AUD Mn)

—3.0821.9010.2750.340

Operating cash flow (AUD Mn)

-3.148-2.595-5.880-6.137-3.260

Capital expenditure (AUD Mn, outflow)

—0.0080.00000.005

Free cash flow (AUD Mn)

—-2.603-5.880-6.137-3.264

Investment in associate Ateria (AUD Mn, outflow)

02.730000

Proceeds from share issues gross (AUD Mn)

—00.0240.3977.149

Share issue transaction costs (AUD Mn)

—000.1240.493

Dividends paid (AUD Mn)

00000

Share buy-backs (AUD Mn)

00000.122

Net change in cash (AUD Mn)

—-5.261-5.552-8.8386.456

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2023FY2024FY2025FY2026

Return on average equity (%)

-17.7-42.9-50.2-38.6

Return on average assets (%)

—-37.0-40.6-31.8

Current ratio (x)

9.205.465.097.17

Debt to equity, borrowings only (x)

0000

Lease liabilities to equity (x)

0.010.010.010.02

Asset turnover (x)

—0.260.570.67

Days inventory outstanding (days, average inventory / COGS)

—503291270

Days sales outstanding (days, year-end trade receivables / revenue)

3.844.039.629.7

Revenue by Region

Product and geographyFY2023FY2024FY2025FY2026

Travelan Australia (AUD Mn)

1.1013.7035.2015.673

Travelan United States (AUD Mn)

0.6431.0761.6581.768

Travelan Canada (AUD Mn)

0.0010.0810.3790.166

Protectyn Australia (AUD Mn)

0.0600.0430.0490.022

ProIBS Australia (AUD Mn)

0000.085

Total (AUD Mn)

1.8054.9037.2877.714

Revenue by Region by Region

RegionFY2023FY2024FY2025FY2026

Australia (APAC) revenue (AUD Mn)

1.1613.7465.2505.780

United States revenue (AUD Mn)

0.6431.0761.6581.768

Canada revenue (AUD Mn)

0.0010.0810.3790.166

North America total revenue (AUD Mn)

0.6441.1572.0371.934

Region growth (%)

Region growth (%)FY2024FY2025FY2026

Australia YoY growth (%)

222.740.210.1

United States YoY growth in A$ (%)

67.354.26.6

Canada YoY growth (%)

6,635367.9-56.3

North America YoY growth (%)

79.776.1-5.1

Region share of revenue (%)

Region share of revenue (%)FY2023FY2024FY2025FY2026

Australia share (%)

64.376.472.074.9

United States share (%)

35.621.922.822.9

Canada share (%)

0.11.75.22.2

Revenue History

PeriodSales (AUD Mn)YoY growth (%)Source

H1 FY2026 (Jul–Dec 2025)

4.25

Release 20 Jan 2026

Q2 FY2026

2.2—

Release 20 Jan 2026 (+11% QoQ)

Q3 FY2026

1.516

Q3 sales update (Apr 2026)

Q4 FY2026

2.02

Release 16 Jul 2026

H2 FY2026

3.57

Release 16 Jul 2026

Valuation Snapshot

MetricValueDate / source

Nasdaq ADS price

US$1.76

9 Sep 2026 (MarketChameleon)

Nasdaq ADS 52-week range

US$0.68 – US$2.39

2025–2026 (RedChip/Yahoo)

ASX price

A$0.043

16 Jul 2026 (Kalkine)

ASX price (indicative earlier points)

A$0.10 (Dec 2023/early 2024); A$0.041 (Jan 2026); A$0.027 (18 Mar 2026)

Google Finance snapshots

Market capitalisation

~US$14.2m

9 Sep 2026 (MarketChameleon)

1-year total return (ADS)

-6.4%

As of Sep 2026 (MarketChameleon)

3-year and 5-year returns

—

Analyst observation from snapshots

Beta

1.38

MarketChameleon (methodology not disclosed)

Valuation Snapshot by Multiple

MultipleValueBasis

Market capitalisation (AUD Mn)

13.9

322.848m shares × A$0.043

Enterprise value (AUD Mn)

4.9

Market cap − cash A$9.02m (no debt; leases ignored)

EV / Sales FY2026 (x)

0.63

EV / A$7.71m

Price / Book FY2026 (x)

1.26

Market cap / equity A$11.0m

Provider Details

ProviderRatingTargetDateNote

Emerging Growth Research

Buy-Extended

US$4.00 (raised from US$3.90)

22 Apr 2026

Methodology: peer EV/Revenue on TTM revenue adjusted for ADS; releases carried "SOURCE: Immuron Limited", suggesting company-distributed research

Yahoo Finance 1-year target

—

US$3.92

Mar 2026

Aggregated

Simply Wall St

——

Apr 2026

States 2 covering analysts

Capital Markets

ItemDetail

Dividend history

None paid or declared; no dividend policy beyond reinvestment

Buybacks

Unmarketable-parcel buy-back (3,805,528 shares, A$121,777) June 2026; no general buy-back authorisation

Credit ratings (Moody's/S&P/Fitch)

Not rated

Debt maturity profile

No borrowings; lease liabilities A$30,606 current and A$158,937 non-current (30 June 2026)

Equity facilities

F-3 shelf (July 2024, up to US$15m over three years); H.C. Wainwright ATM exhausted December 2025

Share Price & Returns

DateShares issuedPrice per ADS (USD)Proceeds (AUD)

8 Jan 2025

2,579,7602.1784226,567

15 Jan 2025

1,801,6802.0971152,300

29 May 2025

135,8001.84359,744

3 Jun 2025

116,6801.82868,216

17 Jul 2025

877,4401.893963,351

18 Jul 2025

473,8801.878234,072

21 Jul 2025

32,909,6402.13742,711,754

20 Oct 2025

1,133,8402.3008100,458

7 Nov 2025

8,495,0801.9631642,228

5 Dec 2025

45,472,0002.08093,596,835

Analyst Conclusions

Management guidance

No quantitative FY2027 guidance. Qualitative milestones (28 August 2026): Q1 FY2027 continued Travelan growth; Q2 portfolio expansion; Q3 IMM-529 partnering progress; Q4 geographic expansion, improved profitability and reduced cash burn. Investment in North American growth is planned. Consensus growth expectations: not available.

Bull case

  1. Pipeline optionality is nearly free. With EV of roughly A$5m (~0.6x sales), any IMM-529 licence with a meaningful upfront payment relative to a ~US$14m market cap — against a US$400m peak-sales estimate and an IND already cleared — could re-rate the stock.

  2. Commercial engine is re-accelerating at the margin. Q3 FY2026 growth of +16% and H2 FY2026 growth of +7% followed a weak H1; Canada's Q4 surge and the Jean Coutu listing suggest FY2027 Canada should grow strongly off a A$0.17m base, while Australia continues at ~10%.

  3. Path to self-funding is visible. Operating burn halved to A$3.26m in FY2026; at 64.5% gross margin, roughly A$4.3m of incremental revenue at flat opex would close the FY2026 gap between gross profit and S&M plus G&A, and the A$9.0m cash balance provides multi-year runway at current burn.

Bear case

  1. Clinical credibility of IMM-124E has been dented. The 866-participant USU field trial missed its primary endpoint; while confounded by third-party product and BID dosing, a partner must still fund a Phase 3 at TID dosing with limited field evidence — the 2024 CHIM showed only 36.4% efficacy.

  2. Growth deceleration and margin erosion. Revenue growth fell from 171.7% to 48.6% to 5.9%; gross margin declined eight points since FY2023, and the business remains reliant on one brand and on a concentrated Australian pharmacy channel that has already destocked once.

  3. Structural dilution and funding fragility. Shares outstanding rose 38% in FY2026, the ATM is exhausted, R&D tax incentive eligibility may end, and if partnering fails the company must either shelve the pipeline or raise again at depressed prices.

Catalysts and monitorables (next 12 months)

Expected timingCatalyst / monitorable
Mid-Oct 2026Q1 FY2027 sales update — tests "continued Travelan growth" milestone
Nov 2026 (expected)2026 AGM — board composition, remuneration votes, strategy update
Q2 FY2027 (Oct–Dec 2026)"Portfolio expansion" — potential new in-licensed product or ProIBS NZ launch
Q3 FY2027 (Jan–Mar 2027)IMM-529 partnering progress (Pullan process)
~19 Feb 2027 (FactSet estimate)H1 FY2027 results — burn rate under North American investment
OngoingFDA EOP2 meeting for IMM-124E (timing dependent on partner)
OngoingAustralian R&D Tax Incentive legislation outcome
OngoingDoD/HJF program revenue and any expansion into a military-relevant multi-pathogen Travelan
OngoingNasdaq ADS price relative to US$1 minimum bid; FPI rule changes

Analyst verdict

Immuron has executed a credible turnaround of its commercial franchise since the COVID trough: Travelan revenue has grown roughly tenfold in four years, gross margins remain in the mid-60s, and the February 2026 Strategic Reset has reduced cash burn by nearly half while recapitalising the balance sheet to A$9.0m with no debt. The company met its own FY2026 guidance and exits the year with a fourth consecutive quarter of growth, an improving Canadian trajectory and a first non-dilutive revenue stream from the U.S. Department of Defense.

Yet the investment case remains finely balanced and highly binary. The operating business is still sub-scale — selling, marketing and corporate costs exceeded gross profit by A$2.8m in FY2026 — and organic growth has slowed to mid-single digits at group level, with single-brand and single-channel concentration. On the pipeline, the regulatory groundwork (two FDA INDs) is genuine, but the clinical evidence base for IMM-124E has weakened after the USU field study, and IMM-529 rests on compelling but purely pre-clinical data from 2017. Management's decision to partner both assets is financially rational but cedes most of the upside, and micro-cap biotechs often struggle to secure meaningful upfronts for Phase 2-ready anti-infective assets.

The current valuation — an enterprise value of roughly A$5m, about 0.6x trailing sales, with the pipeline effectively valued at zero — already discounts considerable failure. This creates asymmetric optionality: a signed IMM-529 licence or demonstrable progress toward EBITDA (ex-R&D) breakeven could drive a re-rating, while continued dilution or a stalled partnering process would likely extend the multi-year share-price decline. On balance, Immuron is a speculative, event-driven holding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundNotes

Steven Lydeamore

Chief Executive Officer

Since 27 Jun 2022

—

Named key person in 20-F; leads investor presentations

Aaron Laurita

Chief Financial Officer

Since 9 Feb 2026

Finance and commercial experience across several sectors (company release)

Replaced Phillip Hains

Olga Smejkalova

Company Secretary

Since 9 Feb 2026

Corporate governance and compliance experience (company release)

Signs SEC Form 6-K filings

Dr Jerry Kanellos

Chief Scientific Officer

CSO per FY2026 20-F; appointed COO Nov 2020 (BusinessNews)

Long-serving scientific lead

Named key person in 20-F

Phillip Hains (former)

CFO and Company Secretary

2013 – 9 Feb 2026

—

Resigned

Board of Directors

NameRoleAppointedIndependenceBackgroundAge (third-party, date uncertain)

Paul Brennan

Non-Executive Chairman

Director 16 Mar 2022; Chair from Jun 2023

Independent (Investing.com)

CEO of PolyNovo Limited (ASX:PNV) 2015–2021; clinical background and multinational commercial experience

62

Daniel Pollock

Non-Executive Director

11 Oct 2012

Independent (Investing.com)

Sole-practitioner commercial lawyer in Melbourne with international practice; seed investor/board member of small unlisted companies

63

Ravi Savarirayan

Non-Executive Director

7 Apr 2017

Independent (Investing.com)

—56

Dr Jeannie (Jeannette) Joughin

Non-Executive Director

1 Jun 2024

Presumed independent

——

“—” = not publicly disclosed.

Governance Detail

Equity award (FY2026)RecipientsQuantityExercise / conversion price (AUD)ExpiryGrant-date fair value per unit (AUD)

Non-executive director options (approved AGM 11 Nov 2025)

Joughin, Pollock, Savarirayan, Brennan — 1,000,000 each

4,000,0000.110

3 Oct 2029

0.0271

Employee performance rights (granted 16 Aug 2025)

Employees (KPI-based, vesting 1–5 years)

2,147,1540.145

16 Aug 2029

0.0640

Major Shareholders

Holder categoryDetailSource

U.S. institutional ADS holders (13F, Q2 2026)

Citadel Advisors added 29,319 ADS (≈US$31k); HRT Financial new position 20,584 ADS; Morgan Stanley, XTX, Two Sigma, Jane Street, Virtu reduced/exited

QuiverQuant 13F summary

Historic insider example

Anastasiou family superfund held 2,494,746 shares (1.10%) — director since departed

Motley Fool AU (date uncertain)

Insider trading

Daniel Pollock exercised 200,000 options at A$0.12 and sold 200,000 shares at A$0.157 (Mar 2024)

InvestSMART

Competitive Landscape

Competitors by Segment

SegmentCompetitorProduct / approachRelative positioning vs Immuron

TD prevention — vaccines / Rx pipeline

Valneva (Nasdaq/Euronext: VALN)

Dukoral (oral cholera vaccine, some ETEC cross-protection in certain markets)

Established travel-vaccine franchise; Rx, not OTC

TD prevention — pipeline

Scandinavian BioPharma

ETVAX oral ETEC vaccine

Clinical-stage; vaccine vs passive immunity

TD prevention — pipeline

Eveliqure Biosciences

ETEC/Shigella vaccines

Named in Immuron 20-F

TD prevention — pipeline

Lumen Bioscience

Oral spirulina-expressed antibodies (TD and CDI)

Most technologically similar; named in 20-F

TD prevention — pipeline

Sigmoid Pharma; Intercell (now Valneva)

Named in Immuron 20-F

—

TD OTC treatment / prevention

Kenvue (Imodium); Procter & Gamble (Pepto-Bismol)

Antidiarrhoeal / bismuth subsalicylate

Dominant brands; symptomatic treatment rather than antibody prophylaxis

TD OTC — probiotics

Biocodex (Florastor/Saccharomyces boulardii) and pharmacy probiotics

Probiotic prophylaxis

Overlapping "travel gut" consumer need

TD Rx

Bausch Health / Salix (rifaximin)

Antibiotic for TD treatment

Standard of care; antibiotic-resistance concerns favour non-antibiotic options

CDI

Vedanta Biosciences

Defined bacterial consortium (VE303)

Named in 20-F

CDI

Acurx Pharmaceuticals

Ibezapolstat (antibiotic)

Named in 20-F

CDI

Ferring (Rebyota); Nestlé Health Science/Seres (Vowst)

Approved microbiome therapeutics for recurrent CDI

Approved products ahead of IMM-529

CDI

Crestone, BiomeBank, Deinove, LPOXY Therapeutics

Antibiotics / microbiome

Named in 20-F

IBS (ProIBS)

Bayer (Iberogast); Opella/Sanofi (Buscopan); peppermint-oil and fibre products

OTC IBS symptom relief

ProIBS is a small new entrant

Peer Comparison FY2026

CompanyLatest FY revenueRevenue growthGross marginR&D intensityNote

Immuron (FY2026, A$)

A$7.7m

5.9%64.5%25.1%

Source: FY2026 4E

Valneva (FY2024)

~€170m total revenues

————

Kenvue (FY2024)

~US$15.5bn

————

Bausch Health (FY2024)

~US$9.6bn

————

Recent Developments

--

Company Snapshot

$5M

Revenue

7

Employees

$14.2M

Market Cap

1994

Founded

Victoria, Australia

Headquarters

SWOT Analysis

Strengths

  • Proven commercial traction: revenue grew from A$0.77m (FY2022) to A$7.71m (FY2026), a 78% four-year CAGR (Appendix 4E series).
  • Attractive gross margin: 64.5% in FY2026 and 65.4% in FY2025, providing operating leverage if volumes scale (FY2026 4E).
  • Debt-free, recapitalised balance sheet: A$9.02m cash, no borrowings, lease liabilities of only A$0.19m at 30 June 2026.
  • Two FDA-cleared INDs: Travelan IND (Dec 2022) and IMM-529 IND 32095 (Nov 2025), lowering regulatory entry friction for a partner.
  • Published efficacy data at commercial TID dosing: 90.5% protection in a 30-subject ETEC challenge (Otto et al., 2011).
  • Non-dilutive U.S. government funding and validation: MTEC grants of A$2.16m (FY2023) and A$2.60m (FY2024); HJF/DoD sub-award with first revenue in May 2026.
  • Regulatory listings in three jurisdictions (AUST L 106709; NPN 80046016; U.S. supplement), plus ProIBS AUST L 482225.

Weaknesses

  • Persistent losses: loss in every year since 1994; accumulated deficit A$84.97m (FY2026 20-F).
  • Single-product concentration: Travelan was 98.6% of FY2026 revenue.
  • Operating costs exceed gross profit: S&M plus G&A of A$7.78m vs gross profit of A$4.98m in FY2026.
  • Sole-source supply: single manufacturers for IMM-124E (Bovogen) and IMM-529 (Syntro Health); contract manufacturing of finished product (Mayne Pharma) (20-F).
  • Thin organisation: ~7 employees; key-person dependence on CEO and CSO named in 20-F.
  • High inventory days: ~270 days in FY2026 (analyst calculation).
  • Gross margin erosion: from 72.5% (FY2023) to 64.5% (FY2026).

Opportunities

  • IMM-529 licence: Lumanity peak U.S. sales estimate US$400m vs a ~US$14m market capitalisation; Pullan engaged July 2026.
  • IMM-124E partner for Phase 3: eligible for FDA EOP2 meeting; Lumanity peak U.S. estimate US$102m.
  • Canada recovery: H2 FY2026 sales up >100%; Jean Coutu listing in Q3 FY2026.
  • U.S. scale-up: U.S. sales +13% in USD FY2026 with FY2027 investment planned in North America.
  • Portfolio extension: ProIBS launched Oct 2025; FY2027 Q2 milestone "portfolio expansion".
  • Military formulation expansion: NMRC/WRAIR Campylobacter/Shigella program and AFRIMS EAEC/EPEC testing could broaden Travelan into a multi-pathogen product.

Threats

  • Negative field-trial read: USU P2TD missed its primary endpoint (Dec 2025), a data point potential partners and regulators will weigh.
  • R&D Tax Incentive reform: May 2026 proposal may make Immuron (>10 years old) ineligible; FY2026 benefit was A$0.78m (20-F).
  • Retailer power: Chemist Warehouse/Sigma inventory reduction dented FY2026 Australian sales.
  • Dilution: share count +38% in FY2026; ATM exhausted; future raises likely if partnering stalls.
  • Currency: stronger AUD cut U.S. growth from +13% (USD) to +7% (AUD) in FY2026.
  • Competition from approved CDI therapies (Rebyota, Vowst) and pipeline TD vaccines/antibody platforms (Lumen Bioscience, Scandinavian BioPharma).
  • Listing compliance and FPI status: ADS traded as low as ~US$0.68 in the past 52 weeks; SEC concept release on FPI definition could raise compliance costs (20-F).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Company states no material impact expected from U.S. pharmaceutical tariffsTravelan sold in U.S. as supplement; tariff exposure limited
Jul 2025FY2025 unaudited sales update — global sales up 49%; North America A$2.0m (+76%)Record year; Canada pipeline fill
17–21 Jul 2025ATM issues incl. 32.9m shares at US$2.1374/ADS (A$2.71m)Replenishes depleted cash
29 Aug 2025FY2025 Appendix 4E: revenue A$7.29m (+48.6%); loss A$5.25m (prelim); cash A$2.83m + A$3.04m term depositLiquidity low point
25 Sep 2025FY2025 Form 20-F / Annual Report lodged—
Oct 2025ATM capacity increased by ~US$2.85m (US$2.07m sold in prior 12 months)Signals further dilution
10 Oct 2025Notice of 2025 AGM (incl. renewal of proportional takeover provisions)Governance
20 Oct 2025ATM issue 1.13m shares—
24 Oct 2025ProIBS launched in AustraliaPortfolio expansion
31 Oct 2025USU P2TD study completed; topline delayed to end-Nov by U.S. government shutdownTimeline slip
Oct–Nov 2025IMM-529 IND submitted; FDA approval of IND 32095 (Nov 2025)Phase 2-ready asset
7 Nov 2025ATM issue 8.5m shares (A$0.64m)—
11 Nov 2025AGM: NED options approved; EBITDA (ex-R&D) breakeven pathway outlinedStrategic framing
3 Dec 2025New DoD sub-award (NMRC/WRAIR via HJF) for Campylobacter and Shigella HBC productsNon-dilutive revenue
4–5 Dec 202545.472m shares issued at A$0.0791 (A$3.5m); ATM exhaustedLargest FY2026 raise
10 Dec 2025USU P2TD topline: primary endpoint missed; Immuron attributes to third-party product, BID dosing and compliance; will propose TID regimen at EOP2Negative read-through for IMM-124E Rx path
11–16 Dec 20253.33m performance rights converted to shares—
20 Jan 2026H1 FY2026 sales A$4.2m (+5%); Q2 A$2.2mGrowth slowdown visible
22 Jan 2026CEO presents at 89th Emerging Growth ConferenceInvestor outreach
9 Feb 2026CFO/Company Secretary Phillip Hains resigns; Aaron Laurita (CFO) and Olga Smejkalova (CoSec) appointedLeadership change after 13 years
25 Feb 2026HY26 results (net loss A$1.92m vs A$2.49m pcp; cash A$10.0m) and Strategic Reset (partner IMM-124E and IMM-529)Pivotal strategic change
5 Mar 2026Coffee Microcaps presentation; Emerging Growth Research flash update, Buy-Extended, PT US$3.90Sponsored-style coverage
~Apr 2026Q3 FY2026 sales A$1.5m (+16%); YTD A$5.7m (+7%); first Jean Coutu salesRe-acceleration
22 Apr 2026EGR raises PT to US$4.00 (ADS then US$0.93)—
May 2026First revenue from DoD/HJF program; Australian Government proposes R&D Tax Incentive changesPositive and negative
Jun 2026Protectyn removed from ARTG; unmarketable-parcel buy-back cancels 3.81m shares (29 Jun 2026)Portfolio and register clean-up
6 Jul 2026Pullan Consulting engaged for IMM-529 partneringExecution on reset
16 Jul 2026FY2026 sales A$7.7m (+6%): Australia A$5.8m (+10%), U.S. A$1.8m (+7% A$; +13% US$), Canada A$0.2m (-55%; Q4 up several-fold)Fourth consecutive growth quarter
20 Jul 2026CEO presents at Kalkine Media webinar—
28 Aug 2026FY2026 preliminary results: revenue A$7.71m; loss A$3.84m (prelim); cash A$9.02m; FY2027 milestones setResults beat Feb guidance
Sep 2026FY2026 Form 20-F filed: audited loss A$3.68m; accumulated deficit A$84.97mAudited figures

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

6 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 0.8 Mn in FY2022 to AUD 7.7 Mn in FY2026.
Immuron Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue0.81.84.97.37.7
Cost of goods sold—0.51.62.52.7
Gross profit—1.33.34.85

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Immuron FY2026 Appendix 4E and Preliminary Final Report — FY2026 (bulletin.webull.com)
  2. Immuron FY2026 Form 20-F — FY2026 (sec.gov)
  3. Immuron FY26 Preliminary Results release (Form 6-K Ex. 99.2) — FY2026 (sec.gov)
  4. FY26 Preliminary Results full release (via QuiverQuant) — FY2026 (quiverquant.com)
  5. Strategic Reset and HY26 presentation (Form 6-K Ex. 99.2) — H1 FY2026 (sec.gov)
  6. HY26 results and Strategic Reset summary — H1 FY2026 (stocktitan.net)
  7. USU P2TD topline release — FY2026 (announcements.asx.com.au)
  8. Clinical trial update (31 Oct 2025) — FY2026 (biospace.com)
  9. New DoD award release (3 Dec 2025) — FY2026 (santelog.com)
  10. CFO/Company Secretary change (Form 6-K) — FY2026 (stocktitan.net)
  11. IMM-529 partnering release (6 Jul 2026) — FY2027 (biospace.com)
  12. FY26 sales update coverage (16 Jul 2026) — FY2026 (kalkinemedia.com)
  13. FY26 sales update coverage (RTTNews) — FY2026 (rttnews.com)
  14. FY2025 Appendix 4E — FY2025 (announcements.asx.com.au)
  15. FY25 global sales release — FY2025 (sec.gov)
  16. FY2025 results coverage — FY2025 (biotechdispatch.com.au)
  17. FY2024 Appendix 4E (Form 6-K Ex. 99.1) — FY2024 (sec.gov)
  18. FY2023 Appendix 4E (Form 6-K Ex. 99.1) — FY2023 (sec.gov)
  19. FY2023 Appendix 4E cash-flow summary — FY2023 (biopharmawatch.com)
  20. Form 20-F FY2017 (incorporation, listings, premises) — FY2017 (sec.gov)
  21. Board changes (31 May 2024) — FY2024 (biospace.com)
  22. Director resignation (3 May 2024) — FY2024 (sec.gov)
  23. Immuron past ASX announcements list — 2020–2023 (immuron.com.au)
  24. Notice of 2025 AGM — FY2026 (announcements.asx.com.au)
  25. ATM capacity increase — FY2026 (panabee.com)
  26. Emerging Growth Research flash update (Mar 2026) — FY2026 (newswire.com)
  27. Emerging Growth Research flash report (Apr 2026) — FY2026 (barchart.com)
  28. Market data (ADS price, market cap) — Sep 2026 (marketchameleon.com)
  29. Directors register — 2026 (investsmart.com.au)
  30. Director backgrounds (fool.com.au)
  31. Name-change history (google.com)
  32. CampETEC interim results — FY2025 (synapse.patsnap.com)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.